paltimatrectinib (PBI-200)

P1, N=29, Terminated, Pyramid Biosciences | Phase classification: P1/2 --> P1

P1/2, N=29, Terminated, Pyramid Biosciences | N=74 --> 29 | Trial completion date: Jun 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jul 2023; Sponsor terminated development of PBI-200

P1/2, N=74, Active, not recruiting, Pyramid Biosciences | Recruiting --> Active, not recruiting

"Pyramid Biosciences, Inc., and Caris Life Sciences® (Caris), today announced a collaboration to enhance identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial (PBI-200-101) of Pyramid's lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor...Caris' tailored MI Trials offering helps match the right patients to the right biopharma trials based on both the individual patient's molecular tumor profile and the eligibility requirements of a given study."

A BaF3 xenograft model encoding the LMNA-NTRK1 gene fusion and G595R solvent front mutation showed superior efficacy with PBI-200 relative to first-generation compounds larotrectinib and entrectinib, and equivalent efficacy to the second-generation compound selitrectinib, in terms of tumor growth inhibition. Together, these data suggest that PBI-200 has potential as a best-in-class, highly CNS-penetrant next generation TRKi. A Phase 1/2 clinical trial evaluating PBI-200 in NTRK fusion-positive patients, including patients with PBT, is ongoing (NCT04901806).

P1/2, N=74, Recruiting, Pyramid Biosciences | Not yet recruiting --> Recruiting

P1/2, N=74, Not yet recruiting, Pyramid Biosciences